Mesenchymal Stem Cells With Adjuvant Dexamethasone in Patients With Alzheimer’s Disease: A Phase IIa Trial
Dementia and Neurocognitive Disorders · 2025 · 24 (4) · 272
DOI: 10.12779/dnd.2025.24.4.272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dementia and Neurocognitive Disorders, 2025. Verfasst von Na Kyung Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, K…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Institute of Information & Communications Technology Planning & Evaluation, Samsung Medical Center.
Themen: Demenz
Abstract (Originalsprache)
Background and Purpose: This phase IIa trial assessed the safety and efficacy of mesenchymal stem cell (MSC) therapy for Alzheimer's disease (AD). An open-label extension (OLE) further explored the adjunctive role of dexamethasone.
Methods
MSCs (n=24) or a saline placebo (n=12) were administered intraventricularly three times at four-week intervals. In the OLE, MSCs and dexamethasone (15 mg, n=5) were administered to patients who received saline in phase IIa. Clinical parameters and cerebrospinal fluid (CSF) markers were evaluated.
Results
MSC therapy exhibited no significant clinical benefits, but was associated with reductions in CSF AD biomarkers (amyloid-beta, phosphorylated-tau, and total-tau) compared to placebo. The MSC group experienced more adverse events (fever, headache, nausea, and vomiting), while co-administration of dexamethasone appeared to attenuate immune-related reactions and limit increases in CSF white blood cell and interleukin-6.
Conclusions
These findings suggest exploratory biological effects of MSCs on AD biomarkers, with dexamethasone potentially mitigating MSC-induced immune responses. Trial Registration: ClinicalTrials.gov Identifier: NCT02054208, NCT03172117, and NCT04954534.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea.
- Cell and Gene Therapy Institute (CGTI), Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.
- Department of Neurology, Seoul National University Hospital, Seoul, Korea.
- Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Korea.
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Neurology, Incheon Sejong Hospital, Incheon, Korea.
ORCID-Profile: Na Kyung Lee, Hyemin Jang, Jung Il Lee, Juhee Chin, Jong Wook Chang, Sang Won Seo, Hyo Jin Son, Duk L Na, Hee Jin Kim
Förderung
- Korea Health Industry Development Institute
- Institute of Information & Communications Technology Planning & Evaluation
- Samsung Medical Center
Zitieren
APA
Lee, N. K., Jang, H., Choi, Y., Hwangbo, S., Lee, S., Lee, J. I., Kim, Y. J., Chin, J., Chang, J. W., Seo, S. W., Son, H. J., Choi, S. J., Na, D. L., & Kim, H. J. (2025). Mesenchymal Stem Cells With Adjuvant Dexamethasone in Patients With Alzheimer’s Disease: A Phase IIa Trial. Dementia and Neurocognitive Disorders, 24(4), 272. https://doi.org/10.12779/dnd.2025.24.4.272
Vancouver
Lee NK, Jang H, Choi Y, Hwangbo S, Lee S, Lee JI, et al. Mesenchymal Stem Cells With Adjuvant Dexamethasone in Patients With Alzheimer’s Disease: A Phase IIa Trial. Dementia and Neurocognitive Disorders. 2025;24(4):272. doi:10.12779/dnd.2025.24.4.272
BibTeX
@article{Lee2025,
author = {Lee, Na Kyung and Jang, Hyemin and Choi, Yejoo and Hwangbo, Song and Lee, Seunghoon and Lee, Jung Il and Kim, Young Ju and Chin, Juhee and Chang, Jong Wook and Seo, Sang Won and Son, Hyo Jin and Choi, Soo Jin and Na, Duk L and Kim, Hee Jin},
title = {Mesenchymal Stem Cells With Adjuvant Dexamethasone in Patients With Alzheimer’s Disease: A Phase IIa Trial},
journal = {Dementia and Neurocognitive Disorders},
year = {2025},
volume = {24},
number = {4},
pages = {272},
doi = {10.12779/dnd.2025.24.4.272}
}
EUVIMED